These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 20533894)

  • 1. Neurokinin-1 receptor antagonists: a comprehensive patent survey.
    Huang SC; Korlipara VL
    Expert Opin Ther Pat; 2010 Aug; 20(8):1019-45. PubMed ID: 20533894
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Fosaprepitant: a neurokinin-1 receptor antagonist for the prevention of chemotherapy-induced nausea and vomiting.
    Navari RM
    Expert Rev Anticancer Ther; 2008 Nov; 8(11):1733-42. PubMed ID: 18983233
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Potential therapeutic targets for neurokinin-1 receptor antagonists.
    Duffy RA
    Expert Opin Emerg Drugs; 2004 May; 9(1):9-21. PubMed ID: 15155133
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Neurokinin 1 receptor antagonists--current prospects.
    Alvaro G; Di Fabio R
    Curr Opin Drug Discov Devel; 2007 Sep; 10(5):613-21. PubMed ID: 17786860
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Aprepitant (EMEND): the role of substance P in nausea and vomiting.
    Prommer E
    J Pain Palliat Care Pharmacother; 2005; 19(3):31-9. PubMed ID: 16219609
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cancer chemotherapy-induced nausea and vomiting: role of mediators, development of drugs and treatment methods.
    Mahesh R; Perumal RV; Pandi PV
    Pharmazie; 2005 Feb; 60(2):83-96. PubMed ID: 15739895
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Point mutation increases a form of the NK1 receptor with high affinity for neurokinin A and B and septide.
    Ciucci A; Palma C; Manzini S; Werge TM
    Br J Pharmacol; 1998 Sep; 125(2):393-401. PubMed ID: 9786514
    [TBL] [Abstract][Full Text] [Related]  

  • 8. P2X purinergic receptor ligands: recently patented compounds.
    Gunosewoyo H; Kassiou M
    Expert Opin Ther Pat; 2010 May; 20(5):625-46. PubMed ID: 20205618
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparative, general pharmacology of SDZ NKT 343, a novel, selective NK1 receptor antagonist.
    Walpole CS; Brown MC; James IF; Campbell EA; McIntyre P; Docherty R; Ko S; Hedley L; Ewan S; Buchheit KH; Urban LA
    Br J Pharmacol; 1998 May; 124(1):83-92. PubMed ID: 9630347
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The oral NK(1) antagonist, aprepitant, given with standard antiemetics provides protection against nausea and vomiting over multiple cycles of cisplatin-based chemotherapy: a combined analysis of two randomised, placebo-controlled phase III clinical trials.
    de Wit R; Herrstedt J; Rapoport B; Carides AD; Guoguang-Ma J; Elmer M; Schmidt C; Evans JK; Horgan KJ
    Eur J Cancer; 2004 Feb; 40(3):403-10. PubMed ID: 14746859
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The role of neurokinin-1 receptor antagonists for the management of postoperative nausea and vomiting.
    Apfel CC; Malhotra A; Leslie JB
    Curr Opin Anaesthesiol; 2008 Aug; 21(4):427-32. PubMed ID: 18660647
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Discovery of a novel, potent and orally active series of gamma-lactams as selective NK1 antagonists.
    Paliwal S; Reichard GA; Shah S; Wrobleski ML; Wang C; Stengone C; Tsui HC; Xiao D; Duffy RA; Lachowicz JE; Nomeir AA; Varty GB; Shih NY
    Bioorg Med Chem Lett; 2008 Jul; 18(14):4168-71. PubMed ID: 18547807
    [TBL] [Abstract][Full Text] [Related]  

  • 13. NK-1 receptor antagonists as antitumor drugs: a survey of the literature from 2000 to 2011.
    Muñoz M; Martinez-Armesto J; Coveñas R
    Expert Opin Ther Pat; 2012 Jul; 22(7):735-46. PubMed ID: 22697287
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Recent advances in the development of melatonin MT(1) and MT(2) receptor agonists.
    Mor M; Rivara S; Pala D; Bedini A; Spadoni G; Tarzia G
    Expert Opin Ther Pat; 2010 Aug; 20(8):1059-77. PubMed ID: 20533893
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Identification, biological characterization and pharmacophoric analysis of a new potent and selective NK1 receptor antagonist clinical candidate.
    Di Fabio R; Alvaro G; Braggio S; Carletti R; Gerrard PA; Griffante C; Marchioro C; Pozzan A; Melotto S; Poffe A; Piccoli L; Ratti E; Tranquillini E; Trower M; Spada S; Corsi M
    Bioorg Med Chem; 2013 Nov; 21(21):6264-73. PubMed ID: 24075145
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Anti-emetic therapy in cancer chemotherapy: current status.
    Herrstedt J; Dombernowsky P
    Basic Clin Pharmacol Toxicol; 2007 Sep; 101(3):143-50. PubMed ID: 17697032
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pathogenesis-based treatment of chemotherapy-induced nausea and vomiting--two new agents.
    Navari RM
    J Support Oncol; 2003; 1(2):89-103. PubMed ID: 15352652
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Aprepitant--where do we stand in the control of chemotherapy-induced nausea and vomiting?
    Sarcev T; Secen N; Zaric B; Milovancev A
    J BUON; 2008; 13(3):333-9. PubMed ID: 18979546
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Establishing the dose of the oral NK1 antagonist aprepitant for the prevention of chemotherapy-induced nausea and vomiting.
    Chawla SP; Grunberg SM; Gralla RJ; Hesketh PJ; Rittenberg C; Elmer ME; Schmidt C; Taylor A; Carides AD; Evans JK; Horgan KJ
    Cancer; 2003 May; 97(9):2290-300. PubMed ID: 12712486
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tachykinin NK2 receptor antagonists. A patent review (2006 - 2010).
    Altamura M
    Expert Opin Ther Pat; 2012 Jan; 22(1):57-77. PubMed ID: 22149761
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.